Barclays raised the firm’s price target on Vir Biotechnology (VIR) to $30 from $26 and keeps an Overweight rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VIR:
- Morning News Wrap-Up: Tuesday’s Biggest Stock Market Stories on Feb. 24
- Vir Biotechnology price target raised to $18 from $14 at Needham
- Video: AMD jumps after expanding partnership with Meta
- Why Is Vir Biotechnology Stock Up Today?
- Vir Biotechnology price target raised to $18 from $12 at Evercore ISI